Note

- These are excerpts from the discussion at JBF ICH-M10 workshop 2023. Please note that these do not represent the official position of JBF.

LBA

NA for LBA

- **Did not discuss** about these topic on JBF M10WS 2023
  - L3: Surrogate/rare/preclinical matrix for LBA
  - L4: Chrom requirements infecting LBA
  - PL-01: Tissues - how are you interpreting the requirements?

LBA

L1: Dilutional Linearity & Parallelism

- **Assess parallelism as a standard MV parameter? ➡ No** (almost all members)
- **One sample is sufficient to assess parallelism? ➡ No** (all members)

Comments

- **If selectivity using patient samples passes**, parallelism for this population may be unnecessary.
- Parallelism of antibody drugs to soluble ligands may be unnecessary **if the addition of ligands or ADA does not affect** the measurement of antibody drugs.
- We are discussing that it may be a good idea to check **whether the value changes by changing the dilution ratio using a study sample near Cmax**.

LBA

L2: Singlicate vs duplicate analysis

- **Was singlicate analysis as standard process before ICH-M10? ➡ No** (almost all members)
- **Is singlicate analysis as standard process after ICH-M10? ➡ No**
  - LBA is **often highly variable**.
  - To monitor **the edge effect**.
  - **Cannot recognize abnormal value** by singlicate analysis.
- **What else is needed to make you move into singlicate analysis?**
  - Cases where there is **no problem with statistical interpretation** even if there are outliers.
  - Example of singlicate analysis (e.g., **trends** in Europe and US)

Comments

- **If small CV can be obtained by measuring a QC sample in duplicate**, then it is possible to measure study samples by singlicate.
- Even if study samples are measured by singlicate, **it should be considered that QC samples are measured by duplicate**.
- **When using Gyrolab, peak shape is an indicator** of whether a singlicate can be adopted.

LBA

L5: Dilution QCs during sample analysis

- **Do you include dilution QCs as standard in sample analysis runs?** ➡ **Yes** (minority) **and No** (majority)

- **Are they solely to cover dilutions outside of the validated bracket of dilution factors?** ➡ **Yes** (some members [others did not respond])

Other topics of this theme were not covered in JBF M10 workshop.

LBA

PL-02: Blood stability and LBA

- **Is it clear when blood stability is required? ➡ Yes**
  - **For LBA**, stability in whole blood is **basically NOT necessary.**
  - For **antibody drugs which are not transferred to blood cells** such as lymphocytes, whole blood stability assessment is **NOT** needed.
  - In some cases, **whole blood stability cannot evaluate.** (e.g., Antibody drugs targeting lymphocytes; they may be transferred to lymphocytes during whole blood stability assessment, and the plasma concentration of them may decrease.)